Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
@Wall Street trader : - goedkeuring filgotinib voor RA in Japan ontbreekt nog en - wat betreft Toledo 3970 : de data fase 2 komen maar in 2021. Belangrijk hier is in hoeveel ziektedomeinen ze de fase 2 onderzoeken zullen opstarten. - de grote verrassing (hopelijk positieve) kan er komen voor GLPG1972.
De NOVESA studie van Galapagos met GLPG1690 (Autotaxin > ATX) in patiënten met scleroderma (SSc) zal snel volgen. Primaire eindpunt 24 weken. > week 49 2019 klaar met rekruteren + 24 weken behandeling = > week 21 2020 laatste dosering (week 18 mei) Orphan drug status = weesgeneesmiddel voor SSc = markt ter grootte van + 100.000 patiënten en nagenoeg geen werkzame medicijnen. Wetenschappelijke abstracts.Conclusie van andere autotaxin inhibitor > preklinische studie in SSc We demonstrate that ATX has an important role in SSc fibrosis . Pharmacologic inhibition of ATX with a novel inhibitor, PAT-048, attenuated dermal fibrosis and IL-6 expression. Knock-down of IL-6 in fibroblasts in vitro abrogated LPA-induced ATX expression, suggesting an autocrine loop for ATX/LPA/IL-6 signaling. Both ATX and IL-6 are increased in SSc skin compared to healthy controls, and LPA-induced IL-6 and IL-6-induced ATX expression are increased in SSc fibroblasts, further supporting an ATX/LPA/IL-6 autocrine loop in SSc. Targeting ATX may thus be an effective new therapeutic strategy for SSc fibrosis. acrabstracts.org/abstract/autotaxin-i...
@WST You’re absolutely right. It’s just frustrating to see a stock getting hammered for a longer period when you know the value is there...... Basic investing skill is patience. It’s just not my best feature..... I can’t add Gala stock to my portfolio. I am invested up to my eyeball’s... It’s easy to take Gala’s performance for granted and consider it to be normal. It isn’t..... Thanks for the excellent overview and have a good one. Cheers Elliot Rabbit
Leuk dat bij Onno alles draait om de Galapagos eilanden. Zo zijn verschillende studies vernoemd naar eilanden binnen de Galapagos groep. O.a. Pinta en Isabela. En geloof het of niet, Genovesa (De nieuwe Filgotinib man bij Gilead) is ook de naam van een Galapagos eiland, Gilead en Galapagos hebben een nieuwe site: In Darwins Footsteps . Charles Darwin was een wetenschapper (ontdekkingsreiziger) die met zijn schip The Beagle (IEX alias van Onno is Beagle06) de Galapagoseilanden aandeed in 1835.hosted.bmj.com/in-darwins-footsteps
Galapagos' stermiddel filgotinib helpt ook patiënten met psoriatische artritis DAVID ADRIAEN Vandaag om 00:39Het Mechelse biotechbedrijf zegt dat zijn reumapil filgontinib ook langdurig werkt als behandeling voor de nauw verwante ziekte psoriatische artritis. Op het jaarlijkse reumatologencongres Eular stelde Galapagos en zijn Amerikaanse partner Gilead nieuwe analyses voor van studies met filgotonib bij patiënten die lijden aan psoriatische artritis. De bedrijven hadden vorig jaar al een studie voorgelegd waaruit bleek dat het kandidaat-medicijn werkt bij een grote groep patiënten. Nu blijkt uit een opvolgstudie van een jaar dat het filgotinib ook op langere termijn werkzaam is en veilig is. Walid Abi-Saad, de medisch directeur van Galapagos, onderstreept dat 'het medicijn snel werkt om de kenmerken van ontsteking te verminderen'. Een grotere studie moet dit nu nog bevestigen, maar Galapagos gaf eerder aan dat Gilead die Fase 3-studie Penguin gepauzeerd heeft door de corona-pandemie.Blockbuster Psoriatische artritis is een van de 10 aandoeningen waarvoor filgotinib wordt getest, naast de hoofdindicatie reumatische artritis. Voor die laatste aandoening zijn alle grote patiëntenproeven afgerond. De dossiers liggen bij de Europese en Amerikaanse geneesmiddelenautoriteiten klaar om groen licht te krijgen. Zij zullen nog dit jaar een oordeel vellen over de markttoelating van deze mogelijke blockbuster. De inzet bij bijkomende ziektes moeten helpen om de hooggespannen verwachtingen van beleggers en analisten voor filgotinib te vervullen. Vorige maand werd het aandeel Galapagos wat afgestraft na testresultaten met filgotinib bij de darmontsteking colitus ulcerosa. Die data waren op zich goed, maar minder overtuigend dan soms gehoopt.www.tijd.be/ondernemen/farma-biotech/...
The information contained in this website is directed exclusively to professionals authorised to prescribe or dispense medicinal products. Thus, the information contained in this website requires specialised training and scientific background for its correct interpretation. learnjakstat.com/ra/pathogenesis-of-i... Experts discuss RA pathogenesis Introducing the JAK-STAT pathway learnjakstat.com/video/KOL-KevinWinth... The role of cytokines in the JAK-STAT pathway learnjakstat.com/video/KOL-PaulEmery.mp4 Regulation of the immune response by the JAK family proteins learnjakstat.com/video/KOL-JanetPope.mp4 Cytokines and JAK family proteins work together to mediate specific cell responses learnjakstat.com/video/KOL-PeterTaylo... To follow our progress and receive the latest content on RA, including valuable teaching materials, enter your details below. learnjakstat.com/ra/sign-up/
C200 schreef op 6 juni 2020 09:51 :
Leuk dat bij Onno alles draait om de Galapagos eilanden.
Ook goed om te zien dat Gilead de ruimte blijft geven om deze visie door te zetten en samen met Galapagos het verhaal van de reis beschrijft op de manier dat Galapagos dit wil delen.
Follow Gilead and Galapagos on Youtube. We at Gilead and Galapagos have forged a new partnership with complementary strengths, a passion for innovation, and a shared vision of transforming the treatment of inflammatory diseases. "In Darwin's footsteps: Adaptation through innovation in RA" is a Gilead and Galapagos organised and funded symposium taking place during the EULAR 2020 E-Congress, looking at the great progress that has been made in the management of rheumatoid arthritis and the improvements that are continually evolving. Introduction to “In Darwin's footsteps Adaptation through innovation in RA” the Gilead and Galapagos organised and funded symposium that is available to EULAR 2020 registrants. Together we look to a brighter future in the management of rheumatoid arthritis. www.youtube.com/watch?v=68F2W3CZNPI Find Symposium details here: hosted.bmj.com/in-darwins-footsteps GILEAD, GALAPAGOS, AND INFLAMMATION www.raneedsinnovation.com/our-commitm...
www.bloomberg.com/news/articles/2020-... AstraZenica Approaches Gilead About Potential Merger AstraZeneca Plc has approached rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal on record, Bloomberg News reports.
www.bloomberg.com/news/articles/2020-... AstraZeneca Is Said to Approach Gilead About Potential Merger AstraZeneca Plc has approached rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal on record. The U.K.-based firm contacted Gilead last month about a possible tie-up, the people said, asking not to be identified because the details are private. AstraZeneca didn’t specify terms for any transaction, they said. While Gilead has discussed the idea with advisers, no decisions have been made on how to proceed and the companies aren’t in formal talks, the people added. AstraZeneca, valued at $140 billion, is the U.K.’s biggest drugmaker by market capitalization and has developed treatments for conditions from cancer to cardiovascular disease. Gilead, worth $96 billion at Friday’s close, is the creator of a drug that’s received U.S. approval for use with coronavirus patients. Gilead is not currently interested in selling to or merging with another big pharmaceutical company, preferring instead to focus its deal strategy on partnerships and smaller acquisitions, the people said. A representative for Gilead couldn’t be reached for comment outside of regular business hours. A spokesman for AstraZeneca said the company doesn’t comment on “rumors or speculation.” Coronavirus Treatment Gilead’s share price has climbed 18% this year as its antiviral drug for Covid-19, remdesivir, worked its way through clinical trials. The stock is still more than a third lower than its 2015 highs. The Foster City, California-based company has seen a steady decline in sales in its hepatitis C franchise and is trying to reinvigorate its drug-development pipeline. Remdesivir, which has an emergency use authorization from the U.S. Food and Drug Administration, has been shown in some early studies to shorten hospital stays for people with Covid-19. SVB Leerink recently forecast that sales of the drug may reach $7.7 billion in 2022. Gilead has been dispensing early rounds of the drug for free, leading some investors to question how the company plans to make money from it in the future. Chief Executive Officer Daniel O’Day has said the company may spend $1 billion on the treatment this year alone. AstraZeneca, led by CEO Pascal Soriot, is helping to manufacture a Covid vaccine developed at the University of Oxford. The U.S. has pledged as much as $1.2 billion to support the efforts as part of Operation Warp Speed, a push to secure vaccines for America. The shot is expected to enter phase III clinical trials in June. Deal Slump Health-care dealmaking has been a rare bright spot as the global pandemic and resulting lockdowns have doused the market for mergers and acquisitions. Global M&A volumes are down about 45% this year, according to data compiled by Bloomberg, and announced deals have been falling apart at a steady pace. Excluding minority investments, dealmaking in April and May barely topped $100 billion in total, the data show, the lowest two-month period in at least 22 years. AstraZeneca is no stranger to large-scale, politically sensitive M&A. In 2014 it fended off a $117 billion approach from Pfizer Inc., a deal that attracted attention from U.S. lawmakers as it would have allowed New York-based Pfizer to lower its tax bill by redomiciling in the U.K. Its shares are up 11% since the start of the year, boosted by positive data from trials of its blockbuster lung cancer drug Tagrisso.
Stanford researcher Genovese joins Gilead to lead NASH, arthritis programs Gilead and partner Galapagos are awaiting an FDA decision on their arthritis drug filgotinib, which was filed with the FDA late last year.This is a major drug for Gilead , which spent $5 billion on a deep pipeline deal with Galapagos last year. Gilead has long had a stake in the late-phase JAK1 inhibitor filgotinib, with recent data readouts showing the med is better than methotrexate alone while suggesting it has an edge over AbbVie’s Humira , the aging blockbuster rheumatoid arthritis incumbent. Results shared to date suggest Gilead has enough positive evidence to get filgotinib approved. The harder question is whether the evidence is strong enough to get filgotinib a cleaner label than its rivals or otherwise give it an advantage that translates into the hoped-for blockbuster sales. The safety of filgotinib is a particular source of ongoing uncertainty. Gilead and Galapagos think filgotinib is free from some of the safety problems that blighted Pfizer's Xeljanz and Eli Lilly's Olumiant and hit multiple members of the JAK family . However, AbbVie’s Rinvoq, which, like filgotinib, is specific to JAK1, received a black box warning when it won FDA approval earlier this year. If approved, this would be the company’s first medicine to treat an inflammatory disease.Genovese , who is now the company's senior vice president of inflammation, will oversee this drug’s development and has overall responsibility for clinical work of its experimental portfolio of treatments for inflammatory conditions. “We are very pleased to welcome Mark to Gilead; he is one of the leading researchers and clinicians in the fields of immunology and rheumatology , and we will benefit tremendously from his expertise as we seek to bring forward new treatments that improve care for patients with rheumatoid arthritis, inflammatory bowel disease and other debilitating conditions,” said Merdad Parsey, M.D., Ph.D., chief medical officer at Gilead. “Gilead has a long history of transforming care for people with serious illnesses, such as HIV and viral hepatitis, and I’ve watched as the company has worked over the past several years to add programs, resources and individuals to bring that same scientific rigor and innovation to patients with inflammatory diseases, where doctors and patients are so much in need of better treatment options,” added Genovese. “In my prior academic role, I had the opportunity to work with Gilead as the company began to grow its work in inflammatory diseases, and I’m excited to join the talented team. I look forward to the progress we will make together to transform care for patients.www.fiercebiotech.com/biotech/stanfor...
Het rotsvaste vertrouwen in Filgotinib en zeker ook GLPG1690 zal zich verder in (doorlopend) rendement gaan uitdrukken. Ik meen dat Galapagos de enige nog is die met IPF (in zo'n vergevorderd stadium) is.
De "vraag" is natuurlijk waarom Gilead enorm heeft geïnvesteerd in Galapagos en hoe het komt dat de grote reuzen altijd op zoek zijn naar nieuwe uitdagingen (zeg maar de financiële positieve prikkels)... grote bedrijven weten dat het niet makkelijk is om een "nieuw wiel uit te vinden"... Een mooi dynamisch bedrijf als Galapagos heeft deze prikkels allemaal in huis!
1. Weet iemand of AZ ook in de running was toen de overeenkomst tot stand kwam met Gilead? 2. Een tijdje geleden werd er over gespeculeerd wanneer Gilead warrant B zou uitoefenen? Toen werd er geopperd dat dit waarschijnlijk zou gebeuren na goedkeuring filgo in de VS. Denken jullie dit nog steeds?
Hier nog een positief recent nieuwsberichtje van The Wall Street Journal... zag hem nog niet op dit draadje.. PRESS RELEASE NEW ANALYSES OF PHASE 2 EQUATOR CLINICAL PROGRAM SUPPORT DURABLE EFFICACY OF FILGOTINIB IN PSORIATIC ARTHRITIS June 5, 2020 4:06 pm ETwww.wsj.com/articles/PR-CO-20200605-9...
Mr Biggy : gelieve maanddraad te gebruiken voor uw 3 type posts : hier enkel inhoudelijk light !
Super, duimpje van mij! Ben me aan het Inlezen...
e-therapeutics en Galapagos werken samen FONDS KOERS VERSCHIL VERSCHIL % BEURS Galapagos 180,75 0,00 0,00 % Euronext Amsterdam (ABM FN-Dow Jones) e-therapeutics en Galapagos gaan samenwerken om nieuwe behandelingen te ontwikkelen voor idiopathische longfibrose. Dit maakte het Britse biotechbedrijf woensdagochtend bekend. Deze samenwerking combineert de expertise van e-therapeutics op het gebied van netwerkbiologie en silico-fenotypische screening met de diepgaande kennis van Galapagos op het gebied van IPF en fibrose. Galapagos betaalt e-therapeutics voor de samenwerking, onder meer wanneer bepaalde mijlpalen zijn behaald. Door: ABM Financial News.info@abmfn.nl Redactie: +31(0)20 26 28 999 © Copyright ABM Financial News B.V. All rights reserved.
Het hele persbericht: Collaboration with Galapagos to discover new therapeutic strategies for the treatment of idiopathic pulmonary fibrosis and other fibrotic conditions Oxford, UK, 10th June 2020: e-therapeutics plc (AIM: ETX.L, "e-therapeutics" or "the Company") today announces that it has entered a collaboration agreement with Galapagos NV ("Galapagos") to identify new therapeutic approaches to modulate a specific mechanism involved in idiopathic pulmonary fibrosis (IPF) and potentially in other fibrotic indications. e-therapeutics will continue to be free to explore, both internally and with additional partners, all other pathways involved in IPF and fibrosis. This collaboration combines e-therapeutics' expertise in network biology and in silico phenotypic screening with Galapagos' deep knowledge of IPF and fibrosis. e-therapeutics will apply its proprietary Network-driven Drug Discovery (NDD) platform and know-how to identify new strategies to modulate a specific pathway of interest to Galapagos, selecting potentially clinically relevant compounds for the treatment of IPF and fibrosis. As part of the collaboration, e-therapeutics will be responsible for all computational activities and Galapagos will perform all experimental testing. Under the terms of the agreement, e-therapeutics will receive upfront and near-term payments material to the cash position of the Company. e-therapeutics is also eligible to receive pre-clinical and clinical development and commercial milestone payments. In the United States, 30-40,000 cases of IPF are diagnosed each year. IPF is associated with a progressive loss of lung function and median survival without therapy is limited to between two and three years. Currently available treatments slow disease progression but prognosis remains poor and IPF is the leading cause of lung transplantation. There is a high unmet need for novel and well-tolerated agents able to reduce lung function decline and improve and prolong patients' lives. Other fibrotic conditions, such as those affecting the liver or the kidneys, affect a significant proportion of the population worldwide and also represent urgent medical needs. Ali Mortazavi, Executive Chairman of e-therapeutics, commented: "We look forward to working with Galapagos on this project in areas of clear unmet medical need such as IPF and fibrosis. This collaboration provides additional validation of our platform and its applications in drug discovery and development. Our platform is scalable and can be applied to all areas of biology, providing an engine for diverse drug discovery projects and enabling us to help partners in numerous ways. This is our third collaboration with a leading biopharmaceutical company, and we remain in business development discussions for both NDD and our functional genomics platform, GAINs."
Some more information about e-Therapeutics. They are an Oxford, UK-based business with a revolutionary computer-based platform and a unique network-driven drug discovery ("NDD") methodology which allows them to discover novel and better drugs faster.www.youtube.com/watch?v=wQFpTtuzrgA Network-driven drug discovery www.etherapeutics.co.uk/media/1211/dt... A Great collaboration deal for Galapagos! tools.euroland.com/tools/PressRelease...
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)